Get started
Author

Xiaoru Zhou

Observed names: Xiao-Ru Zhou, Xiao-ru Zhou
Observed institutions: Chinese Academy of Sciences, ShanghaiTech University, Shanghai Institute of Materia Medica, Jiangsu Hengrui Medicine (China), University of Chinese Academy of Sciences, State Key Laboratory of Drug Research
ORCID: 0009-0005-4490-8947
Observed ORCID: 0009-0005-4490-8947
OpenAlex ID: A5018890101
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis
2021 · He-ming Huang, Shi-jie Fan, et al. · Acta Pharmacologica Sinica · 30
PDF
Natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase
2021 · Wen Li, Li-ping Liao, et al. · Acta Pharmacologica Sinica · 25
PDF
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
2021 · Xiao-ru Zhou, Xiao Li, et al. · Acta Pharmacologica Sinica · 14
PDF
Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation
2021 · He-Ming Huang, Xiao-Ru Zhou, et al. · Molecular Medicine Reports · 14
PDF
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al. · Molecular Cancer Therapeutics · 3
Abstract 2366: Balancing efficacy and toxicity of a fibroblast activation protein dependent tetravalent CD40 agonist antibody for cancer therapy
2024 · Simeng Chen, Yuan Lin, et al. · Cancer Research · 1
Supplementary Table 4 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Table 3 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Table 2 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Table 1 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Data from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Figure 5 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Figure 4 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Figure 2 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Figure 3 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Supplementary Figure 1 from Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al.
Works count: 16
Citation count: 87
H-index: 4
I10-index: 4
Year
Topic
Type